dijous, 24 de juliol del 2014
Intersect ENT prices IPO at low end of range
Intersect ENT prices its initial public offering at $11 per share, the low end of its predicted range, hoping to raise $55 million when XENT shares hit the NASDAQ exchange today.
Intersect ENT said today that it's shares should hit the NASDAQ exchange at $11 apiece, the low end of the range, for expected proceeds of $55 million.
At that price, Intersect would command a market capitalization of roughly $267 million.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1x6NrAN
Abbott CEO chides critics of corporate inversions | Medtech Wall Street news for the week of July 21, 2014
Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Allergan cuts 1,500 jobs, faces SEC complaint; A countdown to failure for Valeant's hostile $53B Allergan takeover; GE Healthcare idles for another quarter
Abbott CEO defends inversions amid corporate exodus furor
July 18, 2014 by Arezu Sarvestani
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1Abq6SN
Boston Scientific beats The Street with Q2 sales, earnings
Boston Scientific beats Wall Street's expectations and its own forecasts for 2nd-quarter sales and earnings, with strong performances from its core implantable cardiac defibrillator and drug-eluting stent businesses.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1Ab8pCF
Medtronic tallies 175 apps for iPhones and iPads | MassDevice.com On Call
Medtech titan Medtronic has developed 175 iOS apps for internal use by its employees, according to Apple.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1AaEaf8
dimecres, 23 de juliol del 2014
Trice Medical reels in $12M, ex-Embrella founder O'Donnell
Trice Medical says it reeled in the 1st tranche of a nearly $12 million Series B round and named ex-Embrella Cardiovascular Jeffrey O'Donnell Sr. as chairman & CEO.
Trice Medical said it raised the 1st tranche of an $11.6 million Series B round and named medtech veteran Jeffrey O'Donnell Sr. as its new CEO.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1x2dKYL
FDA warns CareFusion over modified devices, quality control
The FDA wants CareFusion to stop selling its anesthesia breathing circuit and the Denver ascites shunt and percutaneous access kit until it applies for clearance for changes made to the devices and clears up some quality control issues at a plant in Illinois.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1nqUZwG